The global rise in type 2 diabetes (T2D) and obesity necessitates innovative dietary interventions. This study investigates the effects of allulose, a rare sugar shown to reduce blood glucose, in a rat model of diet-induced obesity and T2D. Over 12 weeks, we hypothesized that allulose supplementation would improve body weight, insulin sensitivity, and glycemic control. Our results showed that allulose mitigated the adverse effects of high-fat, high-sugar diets, including reduced body weight gain and improved insulin resistance. The allulose group exhibited lower food consumption and increased levels of glucagon-like peptide-1 (GLP-1), enhancing glucose regulation and appetite control. Additionally, allulose prevented liver triglyceride accumulation and promoted mitochondrial uncoupling in adipose tissue. These findings suggest that allulose supplementation can improve metabolic health markers, making it a promising dietary component for managing obesity and T2D. Further research is needed to explore the long-term benefits and mechanisms of allulose in metabolic disease prevention and management. This study supports the potential of allulose as a safe and effective intervention for improving metabolic health in the context of dietary excess.

Background: Uric acid (UA), a metabolite of purine and fructose metabolism, is linked to inflammation and metabolic disorders, including gout and cardiovascular disease. Its pro-inflammatory effects are largely driven by the activation of the nucleotide-binding oligomerization domain-like receptor family pyrin domain-containing 3 (NLRP3) inflammasome, leading to increased cytokine production. Beta-hydroxybutyrate (BHB), a ketone produced during fasting or carbohydrate restriction, has been shown to reduce inflammation. This study explores the role of BHB in mitigating the inflammatory and metabolic effects of elevated uric acid levels. Methods: We utilized a murine muscle cell culture treated with UA and BHB. Results: Muscle cells treated with UA had increased production of pro-inflammatory cytokines and reduced cell viability. Co-treatment with BHB reversed these effects, improving cell survival and reducing cytokine levels. Additionally, uric acid impaired mitochondrial function and increased oxidative stress, which were mitigated by BHB. Furthermore, uric acid disrupted insulin signaling, but BHB co-treatment restored insulin sensitivity. Conclusions: These findings suggest that BHB holds therapeutic potential by counteracting the inflammatory and metabolic disruptions caused by elevated uric acid, making it a promising target for conditions such as hyperuricemia and metabolic syndrome.

Gestational diabetes mellitus (GDM) affects placental metabolism, influencing both maternal and fetal outcomes. This study investigated the expression of metabolic regulators—Pyruvate Kinase M2 (PKM2), AMP-activated protein kinase (AMPK), and mTOR pathway components—in placental tissues from GDM pregnancies managed with either insulin (GDM-I) or dietary interventions (GDM-D). We hypothesize that metabolic adaptation in GDM is differentially regulated by treatment modality. This study analyzed 30 cases, including 10 control pregnancies,10 GDM-D cases, and 10 GDM-I cases. Analytical methods included immunofluorescence and immunoblotting. We observed an upregulation of PKM2 in both GDM-I and GDM-D placentas, suggesting enhanced glycolytic adaptation under GDM-induced metabolic stress. AMPK expression was significantly elevated in GDM-I and moderately increased in GDM-D placentas, potentially compensating for insulin resistance by promoting glucose uptake and energy homeostasis. Furthermore, mTOR pathway activation differed by treatment type, suggesting a treatment-specific mTOR response. The metabolic changes observed suggest that treatment modality in GDM may have direct implications for maternal and fetal health. Our findings indicate that while insulin and dietary management support metabolic adaptation in GDM, they do so through distinct mechanisms. These findings support a personalized approach in GDM treatment, where patient-specific metabolic responses should guide therapeutic decisions.

Background/Objectives: Yerba maté (YM), a traditional herbal beverage made from Ilex paraguariensis, contains bioactive compounds like polyphenols and alkaloids known for their metabolic benefits. This study investigates YM’s incretin effects, focusing on glucagon-like peptide-1 (GLP-1) and gastric inhibitory polypeptide (GIP). Methods: Male and female C57BL/6 mice were supplemented with YM for four weeks. Post-supplementation, GLP-1 and GIP gene expression levels were analyzed in jejunal mucosa, and plasma hormone concentrations were measured. Additionally, in vitro experiments were conducted using GLUTag L-cells to evaluate the direct effects of YM and its metabolites, including ferulic acid and dihydroferulic acid, on GLP-1 secretion. Gene expression analysis involved quantitative real-time PCR, while hormone levels were assessed via ELISA. Results: YM supplementation significantly increased GLP-1 gene expression and plasma GLP-1 levels compared to controls, with no changes observed in GIP expression or plasma levels. Direct treatment of GLUTag L-cells with YM did not enhance GLP-1 secretion. However, dihydroferulic acid, a microbial metabolite of ferulic acid, markedly stimulated GLP-1 production in L-cells, highlighting a role of gut-mediated metabolism in YM’s incretin effects. Conclusions: YM selectively upregulates GLP-1 pathways without affecting GIP, likely through gut-mediated mechanisms. These findings suggest YM as a promising nutraceutical for incretin modulation and metabolic disorder management. Further studies should explore the interplay between YM, the gut microbiota, and incretin pathways to fully realize its therapeutic potential.